Clinical significance of serum transforming growth factor-β1 in lung cancer

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 750-753

  Hou, Yu Lei ^a   Chen, Hui ^a   Dong, Zi He ^a   Xue, Cheng Jun ^a   Wu, Yan Feng ^a   Luo, Hai Xia ^a   Wu, Yong Chang ^a   Li, Cheng Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

ELISA; Lung cancer; Transforming growth factor 1

Indexed keywords

CYTOKERATIN; CYTOKERATIN 21 1; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ELISA; LUNG CANCER; TRANSFORMING GROWTH FACTOR Β1;

ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ROC CURVE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84884159602     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.04.013     Document Type: Article

References (19)

1. Ten D.P., Goumans M.J., Itoh S. Regulation of cell proliferation by smad proteins. J Cell Physiol 2002, 191:1-16.
2. Derinck R., Akhurst R.S., Balmain A. TGF beta signaling in tumor suppression. Nat Genet 2001, 29:117-128.
3. Li X., Yue Z., Zhang Y.Y., Bai J., Meng X.N., Geng J.S., et al. Elevated serum level and gene polymorphisms of TGF-β1 in gastric cancer. J Clin Lab Anal 2008, 22:164-171.
4. Papadopoulou E., Anagnostopoulos K., Tripsianis G., Tentes I., Kakolyris S., Galazios G., et al. Evaluation of predictive and prognostic significance of serum TGF-β1 levels in breast cancer according to HER-2 codon 655 poymorphism. Neoplasma 2008, 55:229-238.
5. Sun S.P., Jin Y.N., Yang H.P., Wei Y., Dong Z. Serum transforming growth factor with esophageal carcinoma after radiotherapy. World J Gastroenterol 2007, 13:5267-5272.
6. Schneider T., sailer M., Ansorge S. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006, 79:61-65.
7. Kong F.M., Washington M.K., Jirtle R.L., Anscher M.S. Plasma transforming growth factor beta1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996, 16:47-59.
8. Kong F.M., Jirtle R.L., Huang D.H., Clough R.W., Anscher M.S. Plasma transforming growth factor beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999, 86:1712-1719.
9. Zhang Q., Chen L., Helfand B.T., Jang T.L., Sharma V., Kozlowski J., et al. TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS ONE 2011, 6:1-13.
10. Dong Z.Z., Xiao D.F., Yao M., Qiu L.W., Zong L., Wu W., et al. Clinical impact of plasma TGF-β1 and circulating TGF-β1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008, 7:288-295.
11. Sabrina T.R., Jose P., Alberto A.A., Juliana M.C., Daniel K.A., Jose A.C., et al. TGF-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics 2011, 66:1143-1147.
12. Travis W.D., Brambilla E., Mueller-Hermelink H.K., Harris C.C. World health organization classification tumors of the lung, pleura, thymus and heart 2004, 10-20. IARC Press, Lyon.
13. Shi G.L., Hu X.L., Yu S.D., Song C.X. The value of serum tumor marker in the diagnosis of lung cancer. Zhonghua Zhong Liu Za Zhi 2005, 27(5):299-301.
14. Mumbarkar P.P., Raste A.S., Ghadge M.S. Significance of tumor markers in lung cancer. Indian J Clin Biochem 2006, 21(1):173-176.
15. Domagala K.J., Hoser G., Safianowska A., Grubek J.H., Chazan R. Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp 2006, 54:143-147.
16. 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999, 17:607-614.
17. Sahin C., Osmanli Y., kockar M.C., Seyfettin K., Ömer B., Hüseyin K., et al. The significance of serum transforming growth factor beta1 in detecting gastric and colon cancer. Hepatogastroenterology 2007, 54:1472-1476.
18. Lin Y., Kikuchi S., Obata Y., Yagyu K. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol 2006, 21:432-437.
19. Chu X.Y., Hou X.B., Song W.A., Xue Z.Q., Wang B., Zhang L.B. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer patients with suspicious pulmonary masses. Cancer Biol Ther 2011, 11:995-1000.